Floatz logo

s241656

Histiocytosis

Institut de Recherches Internationales ServierUNKNOWNPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Histiocytosis cohort.

Asset / SponsorPhaseRating
Panitumumab
Institut de Recherches Internationales Servier
Phase 1/2CCC
Cetuximab
Institut de Recherches Internationales Servier
Phase 1/2CCC
Plixorafenib
Fore Biotherapeutics
Phase 1CC

Same molecule, other indications

s241656 is also rated in:

histiocytic and dendritic cell neoplasmActive
CCC
Indicative · Phase 1/2
48 / 100
View asset →
thyroid gland carcinomaActive
CCC
Indicative · Phase 1/2
48 / 100
View asset →
lung cancerActive
CC
Indicative · Phase 1/2
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →